Get started
Author

Shu-Pei Wu

A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
2023 · Ana Ruiz-Garcia, Paul Baverel, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 51
PDF
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
2020 · Alice Tsai, Shu-Pei Wu, et al. · Pulmonary Therapy · 38
PDF
The Effect of ABCG2 and ABCC4 on the Pharmacokinetics of Methotrexate in the Brain
2014 · Ramola Sane, Shu-Pei Wu, et al. · Drug Metabolism and Disposition · 29
PDF
Assessment of Transporter-Mediated and Passive Hepatic Uptake Clearance Using Rifamycin-SV as a Pan-Inhibitor of Active Uptake
2018 · Paresh P. Chothe, Shu-Pei Wu, et al. · Molecular Pharmaceutics · 12
Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
2020 · Alice Tsai, Shu-Pei Wu, et al. · Pulmonary Therapy · 2
PDF
699 Updated safety, PK/PD, and efficacy results from the dose escalation part of a phase I clinical trial of BNT411, a systemic Toll-like receptor 7 agonist, in patients with advanced solid tumors
2024 · Devalingam Mahalingam, Stefan Symeonides, et al. · Journal for ImmunoTherapy of Cancer · 1
Application of Allometric Scaling and Translational Modeling to Predict Human Pharmacokinetics of mRNA-Encoded Antibodies
2026 · Tam N. T. Nguyen, Philip K.-Y. Chang, et al. · Molecular Pharmaceutics
PDF
Kinetic and Dynamic Effects of Intestinal PEPT1 on the Bacterially-Produced Chemotactic Peptide fMet-Leu-Phe and the Anti-Inflammatory Peptide Lys-Pro-Val.
2011 · Shu-Pei Wu · Deep Blue (University of Michigan)
Works count: 8
Citation count: 133
H-index: 4
I10-index: 4
Year
Topic
Type